COVID-19 vaccine safety monitoring in low and middle income countries - Time for a bold new approach
Vaccine
.
2022 Jul 30;40(32):4301-4302.
doi: 10.1016/j.vaccine.2022.06.053.
Epub 2022 Jun 24.
Authors
Walter Straus
1
,
Harvey Rubin
2
Affiliations
1
Moderna, Inc., Cambridge, MA 02139, United States.
2
University of Pennsylvania, School of Medicine, Philadelphia PA 19104, United States. Electronic address: rubinh@upenn.edu.
PMID:
35798593
PMCID:
PMC9226194
DOI:
10.1016/j.vaccine.2022.06.053
No abstract available
MeSH terms
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Developing Countries
Humans
Immunization Programs
Vaccination / adverse effects
Substances
COVID-19 Vaccines